KR20210043624A - 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물 - Google Patents

무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물 Download PDF

Info

Publication number
KR20210043624A
KR20210043624A KR1020217007170A KR20217007170A KR20210043624A KR 20210043624 A KR20210043624 A KR 20210043624A KR 1020217007170 A KR1020217007170 A KR 1020217007170A KR 20217007170 A KR20217007170 A KR 20217007170A KR 20210043624 A KR20210043624 A KR 20210043624A
Authority
KR
South Korea
Prior art keywords
pain
pharmaceutical composition
treatment
dose
ngf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217007170A
Other languages
English (en)
Korean (ko)
Inventor
그레고리 게바
폴라 다킨
스티븐 디마르티노
하이타오 가오
제니퍼 말로니
존 데이비스
캐서린 슈테만-브린
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20210043624A publication Critical patent/KR20210043624A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217007170A 2018-08-10 2019-08-09 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물 Ceased KR20210043624A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862717435P 2018-08-10 2018-08-10
US62/717,435 2018-08-10
US201862764816P 2018-08-15 2018-08-15
US62/764,816 2018-08-15
PCT/US2019/045970 WO2020033872A1 (en) 2018-08-10 2019-08-09 A pharmaceutical composition for safe and effective treatment of knee and/or hip pain

Publications (1)

Publication Number Publication Date
KR20210043624A true KR20210043624A (ko) 2021-04-21

Family

ID=67811008

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217007170A Ceased KR20210043624A (ko) 2018-08-10 2019-08-09 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물

Country Status (10)

Country Link
US (2) US11472870B2 (cg-RX-API-DMAC7.html)
EP (1) EP3833687A1 (cg-RX-API-DMAC7.html)
JP (1) JP7460598B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210043624A (cg-RX-API-DMAC7.html)
CN (1) CN112839956A (cg-RX-API-DMAC7.html)
AU (1) AU2019318556A1 (cg-RX-API-DMAC7.html)
CA (1) CA3108697A1 (cg-RX-API-DMAC7.html)
IL (1) IL280550B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021001549A (cg-RX-API-DMAC7.html)
WO (1) WO2020033872A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7532290B2 (ja) * 2021-03-09 2024-08-13 エヌ・ティ・ティ・コミュニケーションズ株式会社 患者追跡調査支援システム、患者追跡調査支援方法、支援制御装置、端末装置およびプログラム
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023212586A1 (en) * 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
MX2010001395A (es) 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
US8309088B2 (en) * 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
AU2011227335B2 (en) * 2010-03-17 2014-11-06 Abbott Research B.V. Anti-nerve growth factor (NGF) antibody compositions
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
CA2875783C (en) * 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
IL266640B (en) * 2016-11-29 2022-09-01 Regeneron Pharma A pharmaceutical composition for averting opioid addiction

Also Published As

Publication number Publication date
MX2021001549A (es) 2021-04-13
AU2019318556A1 (en) 2021-03-04
JP2021533142A (ja) 2021-12-02
JP7460598B2 (ja) 2024-04-02
WO2020033872A1 (en) 2020-02-13
CN112839956A (zh) 2021-05-25
US20200048337A1 (en) 2020-02-13
CA3108697A1 (en) 2020-02-13
EP3833687A1 (en) 2021-06-16
IL280550B2 (en) 2025-06-01
IL280550A (en) 2021-03-25
IL280550B1 (en) 2025-02-01
US20220041708A1 (en) 2022-02-10
US11472870B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JP6283754B2 (ja) Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法
JP5537740B2 (ja) Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
JP2022078306A (ja) Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
KR20200141461A (ko) 렙틴 수용체 작용제 항체를 사용한 치료 방법
JP2019509271A (ja) Ａｎｇｐｔｌ３の阻害剤を投与することによるアテローム性動脈硬化症の処置又は予防のための方法
US20220041708A1 (en) Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain
KR20200128125A (ko) 신체 조성을 변경하기 위한 방법
US11491222B2 (en) Method of treating lower back pain
US20250011408A1 (en) Methods and compositions for reducing centralized pain
RU2786232C2 (ru) Фармацевтическая композиция для безопасного и эффективного лечения боли колена и/или тазобедренного сустава
US20240002491A1 (en) Methods for selecting patients for treatment with an ngf antagonist
EA044062B1 (ru) Фармацевтическая композиция для предотвращения опиоидной зависимости
HK40011843A (en) A pharmaceutical composition for averting opioid addiction
HK40100361A (zh) 用抗il-13抗体治疗特应性皮炎的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601